vimarsana.com

Page 291 - லண்டன் பள்ளி ஆஃப் சுகாதாரம் வெப்பமண்டல மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

What you need to know about coronavirus on Wednesday, December 30

What you need to know about coronavirus on Wednesday, December 30 CNN 12/30/2020 © Reuters CDC releases illustration of the Coronavirus. The UK today became the first country in the world to approve Oxford University/AstraZeneca s Covid-19 vaccine, the first step on the road for a shot that is cheaper and easier to transport than other vaccines and is expected to help wider areas of the globe emerge from the pandemic. The green light also shores up Britain s race to vaccinate more people against the spread of the virus in the country, which on Tuesday broke its daily record of cases for a second consecutive day. Previously, the team developing the vaccine said that two doses of the shot had an an average efficacy of 70%, with one regimen (a half-dose followed by a full dose) showing an efficacy of 90%. On Wednesday, the UK government announced that the first dose will be given to as many people as possible. Clinicians have also been advised to wait as long as 12 weeks t

Oxford vaccine: More at-risk people will get jab faster in new strategy

Oxford vaccine: More at-risk people will get jab faster in new strategy Robert Dex Experts have agreed a new coronavirus vaccination strategy that will see at-risk people treated more quickly. The scientists, who advise the Government on vaccination, said the focus should be on giving at-risk people the first dose of whichever vaccine they receive, rather than providing the required two doses in as short a time as possible. The Joint Committee on Vaccination and Immunisation (JCVI) said everyone who receives the Pfizer/BioNTech and Oxford University/AstraZeneca vaccines will still receive their second dose within 12 weeks of the first.

The Guardian view on responding to the Covid-19 surge: not enough | Coronavirus

This article is more than 2 months old Millions more are in tier 4 and schools face a delayed return – but tougher action is needed to seize the opportunity offered by the new vaccine A member of staff wearing PPE takes a child’s temperature at a school in London. Photograph: Dan Kitwood/Getty Images A member of staff wearing PPE takes a child’s temperature at a school in London. Photograph: Dan Kitwood/Getty Images Wed 30 Dec 2020 13.58 EST Last modified on Thu 31 Dec 2020 03.27 EST The contrast between the good news and the bleak could not have been starker. The UK’s approval of the low-cost, highly efficacious Oxford/AstraZeneca vaccine represents a shining moment of hope. Never has it been more needed.

Matt Hancock reveals Britain will only have 530,000 doses of Oxford s Covid jab next week

Matt Hancock reveals Britain will only have 530,000 doses of Oxford s Covid jab next week despite promises of 4million by Jan 1 - as it is approved for use amid hopes UK could inoculate 24m by Easter In May, officials suggested 30million doses would be ready by end of year and last month they said 4million But UK ordered 100million doses in total and AstraZeneca promised to deliver 2million a week by mid-January Ministers now face mammoth challenge of trying to rapidly ramp up vaccination capacity in coming weeks

Covid vaccine uptake high despite concerns over hesitancy

Covid vaccine uptake high despite concerns over hesitancy Nicola Davis Science correspondent © Provided by The Guardian Photograph: Ian Forsyth/Getty Images Uptake of the Covid-19 vaccine has been high among those offered it, doctors say, despite fears that vaccine hesitancy could undermine efforts to control the pandemic. Such concerns have been compounded by the new, highly transmissible variant of coronavirus that is spreading across the UK, which will mean a greater proportion of the population needs to be vaccinated to achieve herd immunity. But for now, at least, it seems few are shying away from vaccination. “We’ve had reports from our members that despite inevitable teething problems – to be expected when delivering a completely new and complicated vaccine at scale and speed – the programme seems to be running well overall with very positive take-up rates, so far,” said Prof Martin Marshall, chair of the Royal College of GPs and a practisi

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.